Abstract: Disclosed is a method for supporting a diagnosis of a risk of colorectal cancer recurrence, including the steps of: performing a first measurement to measure the levels of expression of a plurality of genes selected from a first gene group present in a region from 18q21 to 18q23 on the long arm of chromosome 18 in a biological sample collected from a patient with colorectal cancer, a second measurement to measure the levels of expression of a plurality of genes selected from a second gene group present in a region from 20q11 to 20q13 on the long arm of chromosome 20, and a third measurement to measure the levels of expression of a plurality of genes selected from a third gene group including ANGPTL2, AXL, C1R, C1S, CALHM2, CTSK, DCN, EMP3, GREM1, ITGAV, KLHL5, MMP2, RAB34, SELM, SRGAP2P1, and VIM; and determining the risk of colorectal cancer recurrence of the patient based on the levels of expression measured in the measurement step.

Abstract: The invention provides a method for determining presence of a disease, comprising steps of; measuring the levels of expression of transcription products of genes in a biological sample obtained from a subject suspected of having a target disease, wherein the genes comprise at least one gene belonging to each of at least two disease-determining gene families related to the target disease; obtaining values representing deviations by standardizing the levels of the expression based on the levels of expression of transcription products of the corresponding genes in a plurality of healthy subjects; obtaining the average of values representing deviations with respect to the gene belonging to each of the disease-determining gene families; and determining whether or not the subject has the target disease by using the average; as well as a computer program product for determining presence of a disease.

Abstract: Disclosed is a method for supporting a diagnosis of a risk of colorectal cancer recurrence, including the steps of: performing a first measurement to measure the levels of expression of a plurality of genes selected from a first gene group present in a region from 18q21 to 18q23 on the long arm of chromosome 18 in a biological sample collected from a patient with colorectal cancer, a second measurement to measure the levels of expression of a plurality of genes selected from a second gene group present in a region from 20q11 to 20q13 on the long arm of chromosome 20, and a third measurement to measure the levels of expression of a plurality of genes selected from a third gene group including ANGPTL2, AXL, C1R, C1S, CALHM2, CTSK, DCN, EMP3, GREM1, ITGAV, KLHL5, MMP2, RAB34, SELM, SRGAP2P1, and VIM; and determining the risk of colorectal cancer recurrence of the patient based on the levels of expression measured in the measurement step.

Abstract: Methods of judging the lymph node metastasis of stomach cancer, apparatuses for judging the lymph node metastasis of stomach cancer and kits used therefor are disclosed.

Abstract: The present invention relates to novel diagnostic markers for kidney disease and the use thereof.

Abstract: The invention provides a method for determining presence of a disease, comprising steps of; measuring the levels of expression of transcription products of genes in a biological sample obtained from a subject suspected of having a target disease, wherein the genes comprise at least one gene belonging to each of at least two disease-determining gene families related to the target disease; obtaining values representing deviations by standardizing the levels of the expression based on the levels of expression of transcription products of the corresponding genes in a plurality of healthy subjects; obtaining the average of values representing deviations with respect to the gene belonging to each of the disease-determining gene families; and determining whether or not the subject has the target disease by using the average; as well as a computer program product for determining presence of a disease.

Abstract: A treatment solution for preparing a sample solution for nucleic acid amplification reaction is described. The treatment solution comprises dimethyl sulfoxide and aqueous solvent. The sample solution prepared by treating a biological sample with the treatment solution is used in the amplification reaction of a nucleic acid, whereby the nucleic acid can be efficiently recovered from a biological sample, and the influence of an inhibitor during nucleic acid amplification can be effectively reduced.

Abstract: The present invention provides a novel marker capable of accurately diagnosing the lymph node metastasis of stomach cancer. An mRNA, or a fragment thereof, coding for at least one protein selected from TFF1, AGR2, PRSS8, MUC1, MUC4 and MUC17 can be useful as a lymph node metastasis marker.

Abstract: The invention provides a method for judging whether cancer cells are present or not in a sample, comprising a obtaining step of obtaining values related to an expression level of a caner marker gene and a housekeeping gene; a first comparing step of comparing the value related to the expression level of the cancer marker gene with a first threshold value; a normalizing step of normalizing the value related to the expression level of the cancer marker gene based on the value related to the expression level of the housekeeping gene; a second comparing step of comparing the normalized value with a second threshold value; and a judging step of judging whether cancer cells are present or not in the sample based on comparison results obtained in the first and second comparing steps, as well as an apparatus for judging whether cancer cells are present or not.

Abstract: The present invention provides a method of determining whether or not a subject is affected with chronic fatigue syndrome (CFS) comprising: measuring, in a biological sample from the subject, an expression level of a transcript of at least one gene respectively from at least two gene groups selected from six specific gene groups; calculating a value representing a deviation of the measured expression level based on an expression level of a transcript of the corresponding gene in a population of healthy subjects; obtaining an average of the value(s) representing a deviation; and determining whether or not the subject is affected with CFS by using the average.

Abstract: The invention provides a method for determining presence of a disease, comprising steps of; measuring the levels of expression of transcription products of genes in a biological sample obtained from a subject suspected of having a target disease, wherein the genes comprise at least one gene belonging to each of at least two disease-determining gene families related to the target disease; obtaining values representing deviations by standardizing the levels of the expression based on the levels of expression of transcription products of the corresponding genes in a plurality of healthy subjects; obtaining the average of values representing deviations with respect to the gene belonging to each of the disease-determining gene families; and determining whether or not the subject has the target disease by using the average; as well as a computer program product for determining presence of a disease.

Abstract: The present invention provides a means and method for detecting TYR mRNA. As a primer for detecting TYP mRNA, a primer comprising a first sequence at the 5? end side and a second sequence at the 3? end side, wherein the first sequence has 10 to 30 nucleotides in length, and the first sequence is a sequence of a polynucleotide capable of hybridizing with a strand complementary to a first region which is a partial region of SEQ ID NO: 1; and wherein the second sequence has 10 to 30 nucleotides in length, and the second sequence is a sequence of a polynucleotide capable of hybridizing with a second region located in the 3? end side from the first region in SEQ ID NO: 1 is used.

Abstract: Disclosed is a primer for detecting mRNA for CK7. The primer comprises a first sequence on its 5?-terminal side and a second sequence on its 3?-terminal side. The first sequence has a length of 10 to 30 nucleotides, and can hybridize with a strand complementary to a first region which is a region contained in the sequence depicted in SEQ ID NO:1. The second sequence has a length of 10 to 30 nucleotides, and can hybridize with a second region which is located on the 3?-terminal side from the first region in the sequence depicted in SEQ ID NO:1.

Abstract: The invention provides a method for judging whether cancer cells are present or not in a sample, comprising a obtaining step of obtaining values related to an expression level of a caner marker gene and a housekeeping gene; a first comparing step of comparing the value related to the expression level of the cancer marker gene with a first threshold value; a normalizing step of normalizing the value related to the expression level of the cancer marker gene based on the value related to the expression level of the housekeeping gene; a second comparing step of comparing the normalized value with a second threshold value; and a judging step of judging whether cancer cells are present or not in the sample based on comparison results obtained in the first and second comparing steps, as well as an apparatus for judging whether cancer cells are present or not.

Abstract: Methods of judging the lymph node metastasis of stomach cancer, apparatuses for judging the lymph node metastasis of stomach cancer and kits used therefor are disclosed.

Abstract: The present invention provides a novel marker capable of accurately diagnosing the lymph node metastasis of stomach cancer. An mRNA, or a fragment thereof, coding for at least one protein selected from TFF1, AGR2, PRSS8, MUC1, MUC4 and MUC17 can be useful as a lymph node metastasis marker.

Abstract: A method which can objectively determine to what extent a cancer cell has metastasized to a lymph node, the method being a method for determining a size of a metastatic focus, including a step of quantitating a tumor marker mRNA in an assay sample prepared from a lymph node suspected of metastasis of a cancer cell, and a step of obtaining a size of a metastatic focus in the lymph node based on the quantitation result of the mRNA.

Abstract: A method and apparatus for judging the presence or absence of metastasis of malignant tumor is herein described. The method comprising: measuring an absolute amount of a tumor marker; and judging the presence or absence of metastasis of malignant tumor by comparing the absolute amount with a predetermined threshold value. The apparatus comprising: a measuring assembly for obtaining information related to an absolute amount of a tumor marker; and a computer for obtaining absolute amount of the tumor marker based on the information related to the absolute amount of the tumor marker, and judging the presence or absence of metastasis by comparing the absolute amount of the tumor marker with a predetermined threshold value.

Abstract: The object of the present invention is to provide a novel marker for a correct diagnosis of lymph node metastasis of breast cancer. This object is attained by a marker for judging lymph node metastasis of tumor cells derived from breast cancer, the marker including mRNA of the gene encoding Forkhead box A1 (FOXA1) or a fragment thereof.

Abstract: The present invention relates to a primer and method for detecting lymph node metastasis of a cancer cell derived from a colon cancer by detecting a marker in a sample prepared from a lymph node obtained from a living body, wherein the marker is a mRNA or a fragment of the mRNA, the mRNA being transcribed from a gene coding a specific protein.